Track record · closed signal

Pfizer Inc (PFE) — closed signal from April 24, 2026

Partial Published before the outcome was known, scored automatically when the window closed on July 23, 2026 — -4.7% at the close.

Predicted vs. what happened

PFE price · publication thesis → realized outcomesplit-adjusted

$24.12 – $25.05Entry zone — fair-value band

$25.81Published — price the day we called it

$26.70Target — the price the thesis aimed for

$26.67Peak — highest point inside the window, not a realized return

$24.58Window close — end-of-window price, context only

What happened

Partial

Reached 47% of the predicted growth at its peak, without hitting the target.

At window close

-4.7%

realized, from the publication price to the last close inside the window

Peak gain

+3.3%

peak, from the publication price — not a realized return

S&P 500, same window

+3.7%

SPY over the identical days, dividend-adjusted

Window close

$24.58

last close inside the window, ended July 23, 2026

Peak price

$26.67

peak on April 28, 2026 — not a realized return

Days to target

—

The thesis — published April 24, 2026

Predicted growth

+7%

over the measurement window

Target price

$26.70

the price the thesis aimed for

Entry zone

$24.12 – $25.05

the fair-value band we waited for

Price at publication

$25.81

published April 24, 2026

Confidence

63%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Pfizer looks like a beaten-down healthcare name that could bounce if investors favor safer stocks, but the near-term story is weak. Most recent developments apply to the whole industry, not Pfizer specifically, and competitors have stronger progress in obesity drugs, so the path to a clear recovery is limited for now.

Primary drivers

Shares fell enough to allow a short-term stabilization bounce
Defensive healthcare often draws interest when markets wobble
Consistent earnings wins give some support to sentiment
Industry headlines are active, company-specific news is sparse

How it played out

PFE: brief bounce stopped below the target

Lyra published PFE at $25.81 with expected growth of 7%. The thesis called for a short-term bounce but described the near-term story as weak. It pointed to the prior share decline, possible demand for defensive healthcare stocks, consistent earnings wins, and limited company-specific news.

PFE rose to a $26.67 peak on April 28, a gain of 3.3%. That stayed below the $26.70 target, which was never reached. The stock ended the window at $24.58, below its publication price. The bounce partly played out, but the full thesis missed.

What happened during the window

On May 5, Pfizer reported first-quarter results and reaffirmed its 2026 financial guidance. On July 22, Pfizer said the FDA had granted priority review to TALZENNA plus XTANDI for metastatic prostate cancer.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All PFE signals